- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00447382
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Belgrade, Former Serbia and Montenegro, 11000
-
-
-
-
-
Frankfurt, Germany, 60590
-
-
-
-
-
Skopje, North Macedonia, 1000
-
-
-
-
-
Moscow, Russian Federation, 119034
-
-
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type 1 diabetes for at least 12 months
- Basal-bolus treatment for at least 3 months
- Body Mass Index (BMI) less than or equal to 35.0 kg/m^2
- HbA1c (glycosylated haemoglobin) less than or equal to 12.0%
Exclusion Criteria:
- Known or suspected allergy to trial products or related products
- Pregnancy, breast-feeding or the intention to become pregnant or not using adequate contraceptive measures
- Receipt of any trial drug within 1 month prior to this trial
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Conditions that may interfere with trial participation as judged by Investigator: proliferative retinopathy or maculopathy requiring acute treatment within the last six months, recurrent major hypoglycaemia, impaired hepatic or renal function, cardiac problems, uncontrolled hypertension (treated and untreated)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NN304
Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
|
NN304 injected s.c.
(under the skin).
Given as basal insulin.
Injected s.c.
(under the skin).
Given as bolus insulin.
NN729 injected s.c.
(under the skin).
Given as basal insulin
|
Experimental: NN729
Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
|
NN304 injected s.c.
(under the skin).
Given as basal insulin.
Injected s.c.
(under the skin).
Given as bolus insulin.
NN729 injected s.c.
(under the skin).
Given as basal insulin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies
Time Frame: week 0, week 52
|
Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated.
The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture).
The change ratio does not have any unit as it is a ratio.
|
week 0, week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypoglycaemic Episodes
Time Frame: Weeks 0-52
|
Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only.
Major if unable to treat her/himself.
Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.
Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.
Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.
|
Weeks 0-52
|
Glycaemic Control Parameters (Change in HbA1c)
Time Frame: week 0, week 52
|
HbA1c (Glycosylated haemoglobin).
|
week 0, week 52
|
Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])
Time Frame: week 0, week 52
|
week 0, week 52
|
|
Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])
Time Frame: week 0, 26 and 52
|
|
week 0, 26 and 52
|
Change From Baseline in Detemir Specific Antibodies
Time Frame: Week 0, week 52
|
Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated.
The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture).
The change ratio does not have any unit as it is a ratio.
|
Week 0, week 52
|
Change From Baseline in Total Antibodies
Time Frame: Week 0, week 52
|
Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir - human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated.
The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture).
The change ratio does not have any unit as it is a ratio.
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Basophilis)
Time Frame: week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. |
week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Eosinophils)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory.
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Haemoglobin)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory.
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Lymphocytes)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. |
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Monocytes)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. |
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Neutrophils)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. |
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Thrombocytes)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory.
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Haematology - Leucocytes)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. |
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Albumin)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. (ALAT = alanine aminotransferase) |
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory. (ALP = alkaline phosphatase) |
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Creatinine)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Potassium)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Sodium)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory
|
Week 0, week 52
|
Clinical Laboratory Values (Change in Biochemistry - Total Protein)
Time Frame: Week 0, week 52
|
Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52.
Serum samples were analysed at a central laboratory
|
Week 0, week 52
|
Adverse Events
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Global Clinical Registry (GCR, 1452), Novo Nordisk A/S
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX1729-1778
- 2006-004733-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on insulin detemir
-
Montefiore Medical CenterCompleted
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
Rigshospitalet, DenmarkCompletedWeight Gain | Diabetes Type 2Denmark
-
University of Texas Southwestern Medical CenterNovo Nordisk A/SWithdrawn
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesTaiwan
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Denmark
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesIndia
-
Institut de Recherches Cliniques de MontrealNovo Nordisk A/S; McMaster UniversityCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, Puerto Rico